Protalix BioTherapeutics, Inc. (PLX) DCF Valuation

Protalix BioTherapeutics, Inc. (PLX) DCF Valuation

US | Healthcare | Biotechnology | AMEX
Protalix BioTherapeutics, Inc. (PLX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Protalix BioTherapeutics, Inc. (PLX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Protalix BioTherapeutics, Inc.? Our (PLX) DCF Calculator integrates real-world data with extensive customization features, enabling you to adjust forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 54.7 62.9 38.4 47.6 65.5 71.7 78.4 85.8 93.9 102.7
Revenue Growth, % 0 15 -39.03 24.22 37.48 9.42 9.42 9.42 9.42 9.42
EBITDA -8.7 4.5 -18.9 -10.8 11.7 -9.0 -9.9 -10.8 -11.8 -13.0
EBITDA, % -15.89 7.07 -49.4 -22.63 17.79 -12.61 -12.61 -12.61 -12.61 -12.61
Depreciation 1.6 1.3 1.1 1.1 1.2 1.7 1.9 2.1 2.3 2.5
Depreciation, % 2.96 2.07 2.92 2.28 1.82 2.41 2.41 2.41 2.41 2.41
EBIT -10.3 3.1 -20.1 -11.9 10.5 -10.8 -11.8 -12.9 -14.1 -15.4
EBIT, % -18.85 5 -52.31 -24.91 15.97 -15.02 -15.02 -15.02 -15.02 -15.02
Total Cash 17.8 38.5 39.0 22.2 44.6 44.2 48.4 52.9 57.9 63.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 4.7 2.0 3.4 4.6 5.3
Account Receivables, % 8.59 3.18 8.98 9.63 8.05
Inventories 8.2 13.1 18.0 16.8 19.0 21.1 23.0 25.2 27.6 30.2
Inventories, % 14.91 20.8 46.82 35.27 29.08 29.38 29.38 29.38 29.38 29.38
Accounts Payable 6.5 7.2 7.0 5.9 4.3 8.7 9.5 10.4 11.4 12.4
Accounts Payable, % 11.88 11.48 18.22 12.31 6.6 12.09 12.09 12.09 12.09 12.09
Capital Expenditure -.6 -.7 -1.5 -.6 -1.1 -1.3 -1.4 -1.6 -1.7 -1.9
Capital Expenditure, % -1.15 -1.04 -3.8 -1.32 -1.75 -1.81 -1.81 -1.81 -1.81 -1.81
Tax Rate, % 2.97 2.97 2.97 2.97 2.97 2.97 2.97 2.97 2.97 2.97
EBITAT -14.8 7.2 -24.7 -12.3 10.1 -10.7 -11.7 -12.8 -14.0 -15.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -20.2 6.3 -31.6 -13.0 5.7 -8.2 -12.9 -14.1 -15.5 -16.9
WACC, % 8.29 8.29 8.29 8.29 8.23 8.28 8.28 8.28 8.28 8.28
PV UFCF
SUM PV UFCF -52.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -17
Terminal Value -275
Present Terminal Value -185
Enterprise Value -237
Net Debt 3
Equity Value -240
Diluted Shares Outstanding, MM 82
Equity Value Per Share -2.91

What You Will Receive

  • Comprehensive Financial Model: Protalix BioTherapeutics' actual data facilitates accurate DCF valuation.
  • Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
  • Real-Time Calculations: Automatic updates provide immediate feedback as you adjust parameters.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
  • Adaptable and Reusable: Designed for versatility, allowing for ongoing use in detailed financial projections.

Key Features

  • Customizable Clinical Parameters: Adjust essential metrics such as patient response rates, treatment efficacy, and cost of goods sold.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other key financial metrics.
  • Industry-Leading Precision: Leverages Protalix BioTherapeutics' (PLX) actual financial data for accurate valuation results.
  • Effortless Scenario Analysis: Evaluate various assumptions and assess different outcomes with ease.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file for Protalix BioTherapeutics, Inc. (PLX).
  2. Step 2: Review Protalix's pre-filled financial data and forecasts.
  3. Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
  5. Step 5: Analyze the outputs and utilize the results for informed investment decisions.

Why Choose This Calculator for Protalix BioTherapeutics, Inc. (PLX)?

  • Designed for Industry Experts: A sophisticated tool tailored for biopharmaceutical analysts, financial officers, and consultants.
  • Up-to-Date Data: Protalix's historical and projected financials are preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance ensures a smooth calculation process.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for assessing Protalix BioTherapeutics, Inc. (PLX) investments.
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Protalix BioTherapeutics, Inc. (PLX).
  • Students and Educators: Utilize real-world data to enhance financial modeling skills and educational practices.
  • Biotech Enthusiasts: Gain insights into how biotechnology companies like Protalix BioTherapeutics, Inc. (PLX) are valued in the financial market.

What the Template Contains

  • Pre-Filled Data: Includes Protalix BioTherapeutics’ historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Protalix BioTherapeutics’ profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.